The Europe TB diagnostics market size is expected to reach a valuation of USD million by 2030, growing at a apporx. CAGR of 5.3% during the forecast period (2022-2030).
Tuberculosis (TB) is an infectious illness caused by Mycobacterium tuberculosis bacteria (MTB). Tuberculosis is most associated with the lungs, although it may also affect other regions of the body. Most infections are asymptomatic, which is known as latent TB. Roughly 10% of latent infections proceed to active illness, which kills about half of individuals afflicted if left untreated. A persistent cough with bloody sputum, fever, night sweats, and weight loss are all hallmark indications of active tuberculosis. Weight loss gave rise to the historical phrase "consumption." Other organ infections can generate a variety of symptoms.
Active TB symptoms include a chronic cough with bloody mucus, fever, night sweats, and weight loss. The most frequent Europe TB diagnostics market procedure is a skin test; however, blood tests are becoming more widespread
The bacteria Mycobacterium tuberculosis causes tuberculosis, which is an infectious illness (MTB). Tuberculosis usually affects the lungs, but it may also affect other regions of the body. Most TB infections are asymptomatic, known as latent tuberculosis. If left untreated, around 10% of latent infections progress to active disease, killing half of the affected people.
Although there has been significant improvement in tuberculosis diagnosis and treatment over the last decade, tuberculosis (TB) remains a public health problem throughout the European Region. Nations outside the European Union (EU) and Europe Economic Area (EEA) continue to have high rates of tuberculosis (TB) and multidrug-resistant (MDR) TB, whereas EU/EEA countries have a high number of TB cases among vulnerable populations, such as immigrants and prisoners. Men are more affected by tuberculosis than women, and there are larger gaps in case detection and reporting among men. Because of the high number of TB deaths in Europe, governments are taking steps and implementing standards in each country to enhance diagnosis and treatment procedures. Guidelines are mostly accessible in high-income nations that have developed LTBI (Latent Tuberculosis) screening programmes. According to the World Health Organization (WHO), 1.5 million people died from tuberculosis in 2018. (Including 251 000 people with HIV). TB is one of the top ten causes of death worldwide, and the main cause of death from a single infectious agent (behind HIV/AIDS).
The huge increase in the prevalence of this disease across emerging nations is one of the most important drivers that is positively driving market growth in Europe also. For example, during the last several decades, the number of TB patients has increased dramatically. As a result, there has been an increasing desire for research on effective diagnostic technologies to enhance patient outcomes and diagnose these disorders with more accuracy.
As a result of the implementation of these technologies, innovative diagnostics solutions that can diagnose various diseases with greater accuracy and speed have been developed and launched. The WHO Global Tuberculosis Programme, for example, has incorporated an Indian molecular assay called TrueNet as an early diagnosis test for the detection of tuberculosis and the identification of its bacterium strains in around 90 minutes.
Despite a vital and growing need for enhanced detection tools for many illnesses, exorbitant costs are a significant barrier to market expansion in emerging areas. This aspect is likely to impede the broad use of these vital diagnostic tools. Despite the growing number of regulatory approvals and clinical studies in the worldwide market, many well-known firms may be hesitant to participate in it due to a lack of financial resources. This effect might be exacerbated by a drop in product uptake following an increase in the cost of diagnosis.
the market is divided into Sputum smear microscopy, culture-based diagnostics, fast molecular diagnostics, and others are the several types of diagnostics available.
The market is divided into five regions: North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America.
In 2020, Europe will have the third largest Europe TB diagnostics market share, thanks to increased Miagnostics volume in major European nations and rising research and development spending in Europe, which will result in new product releases.
In the WHO Europe Region, 199 700 TB cases were recorded in 2020 from 51 countries and areas13. Incidence TB patients made up 163 602 of the total. Due to the impact of the COVID-19 pandemic on access to TB diagnostic and treatment services, this marks an extraordinary 24.4% decline in the number of notified TB cases compared to 2019. This leads to TB treatment coverage of 71% (95% confidence interval: 62–81%) in 2020, down from 88% (95% confidence interval: 77–100%) in 2019. Armenia and the Republic of Moldova (both 37%), Romania (35%), Belarus (31%), Kyrgyzstan and Lithuania (both 32%), and Ukraine and Tajikistan (30%) were the HPCs with the worst drops. Although Europe has one of the lowest TB burdens in the world, it has the largest number of new MDR-TB patients. The WHO European Region had accomplished the Millennium Development Goal of reversing the TB epidemic. The number of new tuberculosis patients has been declining at a pace of 4.3% each year over the last ten years. TB remains a serious public health problem in the Region, despite the quickest drop in the globe compared to other areas, since MDR-TB rates are the highest in the world. MDR-TB is one of the main causes of the European TB pandemic. In accordance with the Sustainable Development Goals (goal 3.3) and the WHO European policy framework Health 2020, WHO/Europe seeks to eradicate tuberculosis at all levels.
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
October 2021: Qiagen stated that the QIAreach QuantiFeron-TB Test has received CE approval and will be available to identify tuberculosis infection.
BioMerieux announced that its unique and totally automated test VIDAS TB IGRA (Interferon-Gamma Release Assay) to diagnosis latent tuberculosis infection has acquired CE certification.
Oxford Immunotec announced in September 2020 that its TB Spot test for children has been approved by the FDA.
Rache stated that its patented Cobas MTB and Cobas MTB-RIF/INH tests have been included in the current WHO policy guidelines on nucleic acid amplification tests (NAATs) for tuberculosis and drug-resistant tuberculosis diagnosis.